Results
|
1.
|
|
|
2.
|
Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action. MedStar authors:
Citation: - Diabetes Care. 36(7):1807-14, 2013 Jul.
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Baldwin D, Bode BW, Boord JB, Braithwaite SS, Cagliero E, Draznin B, Dungan KM, Falciglia M, Figaro MK, Gilden J, Golden SH, Hirsch IB, Inzucchi SE, Klonoff D, Korytkowski MT, Kosiborod M, Lien LF, Low CC, Magee MF, Masharani U, Maynard G, McDonnell ME, Moghissi ES, PRIDE investigators, Rasouli N, Rubin DJ, Rushakoff RJ, Sadhu AR, Schwartz S, Seley JJ, Umpierrez GE, Vigersky RA, Wexler DJ
|
|
3.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(9):1579-86, 2016 Sep
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
|
|
4.
|
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(6):1706-11, 2014 Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Reaven PD, Schwenke DC, Stentz FB, Tripathy D
|
|
5.
|
Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus. MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(4):909-11, 2014 Apr.
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
All authors: - Christophi CA, Dabelea D, Dagogo-Jack S, Diabetes Prevention Program Research Group, Florez JC, Franks PW, Jablonski KA, Kim C, Knowler WC, Ratner R, Sullivan SD
|
|
6.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
|
|
7.
|
Arsenic exposure, arsenic metabolism, and incident diabetes in the strong heart study. MedStar authors:
- Howard, Barbara V
- Umans, Jason G
Citation: - Diabetes Care. 38(4):620-7, 2015 Apr.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
All authors: - Best LG, Francesconi KA, Goessler W, Gribble MO, Guallar E, Howard BV, Kuo CC, Lee E, Navas-Acien A, Umans JG
|
|
8.
|
Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(9):2622-31, 2014 Sep.
All authors: - Diabetes Prevention Program Research Group, Goldberg RB, Hamman RF, Horton E, Kitabchi A, Larkin M, Mather KJ, Montez MG, Orchard TJ, Perreault L, Temprosa M, Thayer D
|